Quarterly report pursuant to Section 13 or 15(d)

Asset Acquisition - Schedule of Total Consideration, Assets and the Liabilities (Details)

v3.24.2.u1
Asset Acquisition - Schedule of Total Consideration, Assets and the Liabilities (Details) - AlmataBio Transaction - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 6 Months Ended
Mar. 28, 2024
Mar. 27, 2024
Apr. 30, 2024
Jun. 30, 2024
Asset Acquisition, Contingent Consideration [Line Items]        
Stock consideration       $ 12,272
Milestone payment due upon close of private placement investment $ 7,500   $ 7,500 7,500
Milestone payment due upon first patient dosed in a Phase 2 trial       5,000
Transaction costs       2,402
Total GAAP Purchase Price at Close       27,174
Acquired IPR&D       27,641
Cash       356
Accrued expenses and other current liabilities       (823)
Total net assets acquired and liabilities assumed       $ 27,174
Common stock shares issued (in shares)   171,605    
Shares issuable in common stock (in shares)   2,412    
Convertible preferred stock, shares issued upon conversion (in shares)   2,412,000    
Closing stock price (in dollars per share)   $ 4.75